Editorial: Toxicity Mechanism and Clinical Features of PD-1/PD-L1 Inhibitors in Treatment of Cancer, Volume I

Xiangyi Kong, Ryan J. Sullivan, Caisheng Wu, Lin Zhang, Yu JiangFrontiers in Pharmacology 2022 · DOI · OpenAlex

TL;DR

This editorial summarizes a specialized collection of eight articles investigating the "double-edged sword" of PD-1/PD-L1 inhibitors. While these immunotherapies have revolutionized oncology, they trigger a unique spectrum of immune-related adverse events (irAEs); this Research Topic explores the clinical predictors, biological mechanisms, and management strategies for these toxicities across various cancers.

What Problem Does This Paper Address?

The advent of Programmed Cell Death Protein 1 (PD-1) and its ligand (PD-L1) inhibitors has caused a paradigm shift in cancer treatment, moving away from broad-spectrum chemotherapy toward targeted immunotherapy. However, by "releasing the brakes" on the immune system, these drugs can inadvertently cause the body to attack its own healthy tissues.

These toxicities, known as immune-related adverse events (irAEs), are highly variable and depend on the specific drug used, the type of cancer, and individual patient factors. The challenge for clinicians and researchers is twofold:

  1. Predictive Modeling: Identifying which patients are at highest risk for severe toxicity.
  2. Mechanistic Understanding: Deciphering the molecular pathways (e.g., cytokine storms or specific T-cell infiltrations) that drive these side effects to develop better mitigation strategies.

Methods

As an editorial, this paper synthesizes findings from a "Research Topic" consisting of five original research articles and three comprehensive reviews. The contributing studies employed several distinct methodological approaches:

  • Pharmacovigilance Analysis: Mining large-scale adverse event databases to find statistical "signals" of rare toxicities.
  • Retrospective Clinical Cohorts: Analyzing patient records (e.g., in Urothelial Carcinoma or Gastric Cancer) to correlate clinical markers with survival and toxicity outcomes.
  • Biomarker Validation: Adapting and testing scoring systems like the GRIm-Score and CONUT (Controlling Nutritional Status) score to predict patient prognosis.
  • Literature Synthesis: Reviewing current data on rare but fatal complications like immunotherapy-induced myocarditis.

Datasets

The summarized research utilized several key data sources:

  • JADER (Japanese Adverse Drug Event Report): Used to analyze vasculitides and rheumatic toxicities from 2004 to 2020.
  • FAERS (FDA Adverse Event Reporting System): Used to investigate the association between PD-1/PD-L1 inhibitors and pancreatic injuries.
  • Clinical Cohorts: Specific datasets from hospitals in China, Japan, and Europe covering Hepatocellular Carcinoma (HCC), Gastric Cancer, and Urothelial Carcinoma (UC).

Key Insights and Ideas

  • Demographics Influence Risk: One study highlighted that female patients and those aged ≥70 are at a significantly higher risk for developing polymyalgia rheumatica when treated with nivolumab or pembrolizumab.
  • The Cost of Combination Therapy: While combining PD-1 inhibitors with chemotherapy often improves disease control, it comes at a steep price. In Urothelial Carcinoma, the incidence of severe (Grade 3–4) toxicities jumped from 32% in monotherapy to 89% in combination therapy.
  • Nutrition as a Prognostic Tool: The CONUT score (based on albumin, cholesterol, and lymphocyte count) proved to be a strong predictor of survival in gastric cancer patients. Patients with poor nutritional status had significantly shorter progression-free survival.
  • The Mechanism of Myocarditis: A review of immunotherapy-induced myocarditis (a rare but often fatal event) suggests the pathology is driven by T-lymphocyte infiltration and a synergistic inflammatory response, particularly when PD-1 inhibitors are combined with CTLA-4 inhibitors.

Key Results

  • Vasculitis Signals: Analysis of the JADER database confirmed a significant signal for vasculitides associated with nivolumab.
  • Pancreatic Toxicity: Using FAERS data, researchers found that anti-PD-L1 agents had a stronger association with pancreatitis, while anti-PD-1 agents were more closely linked to the development of diabetes mellitus.
  • Predictive Accuracy: The adapted GRIm-Score for HCC patients achieved an Area Under the Curve (AUC) of 0.719, outperforming some traditional staging systems in predicting overall survival.
  • Safety in Blood Cancers: A review of hematological malignancies found that while toxicities occur, the incidence and distribution are roughly similar to those seen in solid tumor oncology, suggesting a level of safety consistency across cancer types.

Limitations and Future Work

The authors acknowledge that current findings are "only the tip of the iceberg." Key limitations and areas for future research include:

  • Data Source Constraints: Much of the current evidence relies on retrospective data or Phase 1/2 trials, which may not capture the full complexity of real-world clinical practice.
  • Need for Education: There is a pressing need for clinicians to acquire more specialized immunological knowledge to make faster, more accurate diagnoses based on subtle toxicity manifestations.
  • Prospective Validation: Future work must focus on prospective trials to validate the predictive scores (like CONUT and GRIm) mentioned in this volume to ensure they are robust enough for routine clinical use.

Summary updated

Abstract

EDITORIAL article Front. Pharmacol., 05 May 2022Sec. Predictive Toxicology https://doi.org/10.3389/fphar.2022.898368
BibTeX
@inproceedings{kong2022editorial,
  author = {Xiangyi Kong and Ryan J. Sullivan and Caisheng Wu and Lin Zhang and Yu Jiang},
  title = {{Editorial: Toxicity Mechanism and Clinical Features of PD-1/PD-L1 Inhibitors in Treatment of Cancer, Volume I}},
  booktitle = {Frontiers in Pharmacology},
  year = {2022},
  doi = {10.3389/fphar.2022.898368},
}

Loading related content...

Figure